TIAA CREF Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

TIAA CREF Investment Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$134M	Buy	+6,555,742	New	+$132M	0.09%	205

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

TIAA CREF Investment Management's TAK Position: Q1 2019 in Review

TIAA CREF Investment Management opened a new position in Takeda Pharmaceutical (TAK) in Q1 2019: 6,555,742 shares worth $134M. The stake represents 0.09% of the portfolio and ranks #205 among its holdings.

390 funds tracked by Wall St. Rank hold TAK as of Q1 2019.

TIAA CREF Investment Management held 6,555,742 shares of Takeda Pharmaceutical worth $134M as of Q1 2019.
Takeda Pharmaceutical was a new TIAA CREF Investment Management position in Q1 2019.
Takeda Pharmaceutical made up 0.09% of TIAA CREF Investment Management's portfolio in Q1 2019, its #205 holding.
390 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.